SI-BONE Q1 revenue $52.6M (+11%), net loss improves 33.8%; raises FY26 guidance

SI-BONE, Inc.

2026-Q1 EPS reported -$0.10 vs consensus -$0.19 ▲ beat (+48.1%)

Worldwide revenue $52.6M (+11.2% YoY); US revenue $49.3M (+10.0%), international $3.3M (+33.9%).
Net loss $4.3M (-33.8% YoY, -$0.10 diluted EPS); adjusted EBITDA $2.5M (vs $0.5M, >440% improvement).
Gross margin stable at 79.8%; operating loss improved 31.9% to $5.1M.
Raised FY2026 revenue guidance to $230-233M (prior $228.5-232.5M); gross margin ~79% (prior ~78%).
Operational: over 1,650 active US physicians (+17%); CMS proposes new MS-DRG for complex spinal fusion with iFuse Bedrock Granite.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

SI-BONE, Inc. reported quarter ended March 31, 2026 results: revenue $52.6 million, net income $4.3 million, EPS $0.10 per diluted share. Guidance raised.

Period: quarter ended March 31, 2026
Revenue: $52.6 million
Net income: $4.3 million
EPS: $0.10 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

physician engagement and ~440% improvement in adjusted EBITDA First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $52.6 million, representing growth of 11.2% • U.S. revenue of $49.3 million, representing growth of 10.0% • Gross margin of 79.8% • Net loss of $4.3 million, representing an improvement of

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-26-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.